2024-519359-27-00招募中2 期
A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 160
- 试验地点
- 2
- 主要终点
- Time to first improvement in CTCAE grading for proctitis is defined as the number of days from Baseline to the first occurrence of a lower CTCAE grading compared to Baseline, sustained for at least three consecutive days
研究概览
简要总结
To prove the superiority of an 8-week rectal treatment with 4 mg budesonide suppositories once daily versus placebo suppositories in improving CTCAE grading for proctitis in the treatment of RAP
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Age and Sex: - Male patients (i.e., sex assigned at birth inclusive all gender identities) aged at least 18 years, at the time of signing the informed consent
- •Type of Participant and Disease Characteristics: - Diagnosis of prostate carcinoma (primary or biochemical recurrence); - Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤2 or Karnofsky performance status 70% (refer to Table
- •Karnofsky performance status); - Local radiotherapy by external beam radiation planned; - Conventional external beam RT with 60-80 Gy complete dose in 20-40 fractions over 4-8 weeks
- •Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤2 or Karnofsky performance status 70%
- •Local radiotherapy by external beam radiation planned.
- •Conventional external beam RT with 60-80 Gy complete dose in 20-40 fractions over 4-8 weeks.
- •Signed informed consent as described in Section 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •CTCAE grading for proctitis and diarrhea ≥ grade 1 for at least 3 days.
- •Sufficient compliance in ePRO as assessed during screening period (defined as at least 3 ePRO entries per week).
排除标准
- •Treatment by brachytherapy
- •Concomitant medication with systemic and/or topical corticosteroids, other immunosuppressants, or medication that affect peristalsis and/or the intestinal mucosa (e.g., antibiotics, loperamide, opioids, laxatives)
- •Participation in another clinical study and having received an IMP within 30 days prior to Visit 0 (Screening visit) or within 5 half-lives of IMP, whichever is longer
- •Crohn’s disease, indeterminate colitis, ischemic colitis, ulcerative colitis, microscopic colitis (i.e., collagenous colitis or lymphocytic colitis)
- •Grade III internal hemorrhoids
- •Perianal dermatitis
- •Significant bacterial, amoebic, fungal, or viral infections of the gut
- •History of any RT in the area of the pelvis and/or the lower abdomen
- •Active colorectal cancer or a history of colorectal cancer
- •Active malignancy other than prostate cancer or treatment with antineoplastic drugs during the last 5 years. Patients with a history of cancer (other than prostate cancer) and at least 5 years of uneventful follow-up and no signs of recurrence may be eligible
- •Phenylketonuria
- •Severe renal impairment (GFR ≤ 29 ml /min /1.73 m2 at Baseline) calculated by CKD EPI 2009
- •Known intolerance/hypersensitivity/resistance to the IMP and excipients or drugs of similar chemical structure or pharmacological profile.
- •Known to be or suspected of being unable to comply with the clinical study protocol (e.g., no permanent address, history of drug abuse, known to be non-compliant, or presenting an unstable psychiatric history).
- •Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the clinical study.
- •Patients in custody by juridical or official order or patients who are institutionalized because of legal or regulatory order.
- •Patient, who is a member of the staff of the study center, staff of the sponsor or clinical research organization, the investigator him-/herself or close relatives of the investigator.
- •Patients with morning serum cortisol serum < 4 µg/dL
- •Active infections, clinically apparent uncontrolled hypertension, diabetes mellitus (including familiar predisposition), active peptic ulcer, osteoporosis, glaucoma, cataract, or other conditions where corticoids may have side effects if careful medical monitoring is not ensured in the opinion of the investigator
- •Immunocompromised patients (e.g., due to human immunodeficiency virus infection) (respective diagnosis in medical history).
- •Diagnosis of chickenpox, herpes zoster, or measles within 3 months prior to Baseline
- •Portal hypertension or liver cirrhosis
- •Abnormal hepatic parameters (ALT, AST or AP > 2.5 x upper limit of normal) or known significant functional disorder of the liver
- •Having received live vaccine(s) within the last 14 days prior to Baseline
结局指标
主要结局
Time to first improvement in CTCAE grading for proctitis is defined as the number of days from Baseline to the first occurrence of a lower CTCAE grading compared to Baseline, sustained for at least three consecutive days
Time to first improvement in CTCAE grading for proctitis is defined as the number of days from Baseline to the first occurrence of a lower CTCAE grading compared to Baseline, sustained for at least three consecutive days
次要结局
- Percentage of participants with reduction in CTCAE grading for proctitis by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4
- Time to first improvement in CTCAE grading for diarrhea after Baseline, where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days
- Percentage of participants with reduction in CTCAE grading for diarrhea by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4
- Time to first improvement in CTCAE grading for rectal pain after Baseline, where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days
- Percentage of participants with reduction in CTCAE grading for rectal pain by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4
- Time to first improvement in each CTCAE grading for further terms of the lower GI composite (fecal incontinence, lower GI hemorrhage, GI pain and other GIdisorder), where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days
- Percentage of participants with reduction in each CTCAE gradings for further terms of the lower GI composite (fecal incontinence, lower GI hemorrhage, GI pain and other GI-disorder) by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4
- Course and change from Baseline in the SHS-GI sum score and sub-scores at Visit 2, 4, and 5
- Course and change from Baseline in the PGI-S at Visit 2, 4, and 5
- PGI-C at Visit 2 and 4
- Course and change from Baseline in the EPIC Bowel Domain Score at Visit 2, 4, and 5
- Therapeutic success at Visit 4, defined as complete relief or marked improvement of symptoms according to the PGA
- Therapeutic benefit at Visit 4, defined as at least a slight improvement according to the PGA
- Assessment of efficacy by investigator and participant at Visit 4
- Percentage of participants who remained symptom-free for at least ten consecutive days at Visit 4
- Percentage of participants who used rescue medication at Visit 4.
- Duration of rescue medication use at Visit 4
- Assessment of tolerability by investigator and participant at Visit 4
- Average daily bowel movement frequency within the treatment period
- Percentage of days within the treatment period with pain during bowel movements
- Percentage of days within the treatment period with mild pain during bowel movements
- Percentage of days within the treatment period with moderate pain during bowel movements
- Percentage of days within the treatment period with severe pain during bowel movements
- Percentage of days within the treatment period with bloody stool
- Percentage of days within the treatment period with mucous stool
- Percentage of days within the treatment period with uncontrolled bowel movements
- Percentage of days within the treatment period during which no pads were used due to uncontrolled bowel movement
- Percentage of days within the treatment period during which pads were used sometimes due to uncontrolled bowl movement
- Percentage of days within the treatment period during which pads were used most of the time due to uncontrolled bowl movement
- Percentage of days within the treatment period during which symptoms interfered with daily life
- Percentage of days within the treatment period during which symptoms interfered with daily functioning to the extent that self-care was impossible
- Percentage of days within the treatment period during which medical intervention was required due to symptoms
研究者
Claudia Stosnach
Scientific
Dr. Falk Pharma GmbH
研究点 (2)
Loading locations...
相似试验
终止
2 期
Budesonide Foam Versus Placebo for Prevention of Acute Radiation ProctitisRadiation ProctitisNCT00828230Dr. Falk Pharma GmbH17
招募中
4 期
A trial to compare efficacy and tolerability of Plenvu® and Picoprep® as cleansing agents of the large bowel before colonoscopy (examination of
the bowel with a fiberoptic device)2024-518544-21-00Aalborg University Hospital400
招募中
4 期
Budesonide as a treatment for inflammation in stomach complaints.Functional Dyspepsia2024-517035-43-00UZ Leuven56
招募中
3 期
Clinical study to demonstrate the same clinical efficacy and tolerability of budesonide orodispersible tablets (taken twice a day compared to once a day) for the treatment of esophagus inflammation in adultseosinophilic esophagitis2024-515229-26-00Dr. Falk Pharma GmbH234
已完成
3 期
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or ProctosigmoiditisProctosigmoiditisProctitisNCT01008423Bausch Health Americas, Inc.281